- Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.Fierce Biotech · 6d ago↗ source
- Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsLupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…Fierce Biotech · 7d ago↗ source
- Roche taps Foundation Medicine’s chief as new North America Diagnostics lead, creates new commercial roleDan Malarek is leaving his role as chief executive of Roche’s sequencing subsidiary Foundation Medicine as he takes up the mantle as President and CEO of Roche Diagnostics North America.